89bio Hopes Akero’s Success In Cirrhotic NASH Is Positive For FGF21 Class

 
• By Joseph Haas
  
Competitive edge and business advantage concept as a group of hot air balloons racing to the top but an individualleader with a small balloon attached giving the winning competitor an extra boost.
89bio has a plan to compete in NASH and the FGF21 analog space
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D